EL PASO, Texas
Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, announced that they have engaged the services of an agent in India. The agent will act in Premier’s interests in locating and securing financing and suitable joint venture partners in India and Asia for the purposes of testing, registering and marketing medications and devices being developed by Premier for the treatment of various diseases, such as fibromyalgia, MS, and cancer.
William A. Hartman, President and CEO of Premier Biomedical, stated, “We believe there are significant advantages in seeking a joint venture with an Indian partner, and see this as the first step to expanding into the entire Asian market through such a mutually beneficial arrangement. While we continue our JV negotiations in Brazil, we believe it is in our best interests to also engage in the pursuit of a similar joint venture arrangement in Asia, which represents about half of the world’s population.”
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” http://www.premierbiomedical.com/
Safe Harbor Notice
Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160308005620/en/
CONTACT
Premier Biomedical, Inc.
William A. Hartman, 724-633-7033
President
and CEO
PR@premierbiomedical.com
